A5042513487- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Nanoparticle-Based Drug Delivery
- Alzheimer's disease research and treatments
- Immune Cell Function and Interaction
- Lipid Membrane Structure and Behavior
- RNA Interference and Gene Delivery
- T-cell and B-cell Immunology
- Viral-associated cancers and disorders
- Supramolecular Self-Assembly in Materials
- Immunotherapy and Immune Responses
- Drug Transport and Resistance Mechanisms
- CNS Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Advanced biosensing and bioanalysis techniques
- Immunodeficiency and Autoimmune Disorders
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Cholinesterase and Neurodegenerative Diseases
- Nanoplatforms for cancer theranostics
- Graphene and Nanomaterials Applications
- Nanocluster Synthesis and Applications
- Monoclonal and Polyclonal Antibodies Research
- Advanced Drug Delivery Systems
- Phagocytosis and Immune Regulation
University of Milano-Bicocca
2016-2025
Ospedale di Parma
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2007-2025
Azienda Ospedaliera San Gerardo
2025
University of Parma
2016-2024
Institute of Biomedical Science
2022
Ministero della Salute
2022
Humanitas University
2022
Leukemia and Lymphoma Society
2022
Azienda Unita' Sanitaria Locale di Parma
2022
Patients with indolent non-Hodgkin lymphoma typically respond well to first-line immunochemotherapy. At relapse, single-agent rituximab is commonly administered. Data suggest the immunomodulatory agent lenalidomide could increase activity of rituximab.A phase III, multicenter, randomized trial plus versus placebo was conducted in patients relapsed and/or refractory follicular or marginal zone lymphoma. received for 12 cycles once per week 4 weeks cycle 1 and day 2 through 5. The primary end...
Engineered nanoparticles offer the chance to improve drug transport and delivery through biological barriers, exploiting possibility leave blood circulation traverse endothelial vascular bed, blood–brain barrier (BBB) included, reach their target. It is known that gather molecules on surface upon contact with fluids, forming "protein corona", which can affect fate therapeutic/diagnostic performance, yet no information corona's evolution across has been gathered so far. Using a cellular model...
PURPOSE To prospectively validate the use of a simplified geriatric assessment (sGA) at diagnosis and to integrate it into prognostic score for older patients with diffuse large B-cell lymphoma (DLBCL). METHODS We conducted prospective Elderly Project study on DLBCL than 64 years who underwent our Fondazione Italiana Linfomi original (oGA) (age, Cumulative Illness Rating Scale Geriatrics, activities daily living, instrumental living) before treatment. Treatment choice was left physician's...
Alzheimer's disease is characterized by the accumulation and deposition of plaques β-amyloid (Aβ) peptide in brain. Given its pivotal role, new therapies targeting Aβ are demand. We rationally designed liposomes brain promoting disaggregation assemblies evaluated their efficiency reducing burden mouse models. Liposomes were bifunctionalized with a derived from apolipoprotein-E receptor-binding domain for blood–brain barrier phosphatidic acid binding. Bifunctionalized display unique ability...
The multiplicity of systems affected in Alzheimer's disease (AD) brains calls for multi-target therapies. Although mesenchymal stem cells (MSC) are promising candidates, their clinical application is limited because risks related to direct implantation the host. This could be overcome by exploiting paracrine action. We herein demonstrate that vivo systemic administration secretome collected from MSC exposed vitro AD mouse brain homogenates (MSC-CS), fully replicates cell-mediated...
Secondary CNS lymphoma is a rare but potentially lethal event in patients with diffuse large B-cell lymphoma. We aimed to assess the activity and safety of an intensive, CNS-directed chemoimmunotherapy consolidated by autologous haematopoietic stem-cell transplantation (HSCT) secondary
Resveratrol (Res) has been reported to possess cancer chemopreventive activity on the basis of its in vitro effects tumor cells and vivo experimental models rodents transplanted with parental tumors or treated carcinogens. We investigated Res development mammary appearing spontaneously HER-2/neu transgenic mice at an early age. The mechanisms involved antitumor effect were evaluated by studying immune effectiveness, apoptosis expression mRNA protein for tumoral glands from Res-treated cell...
Purpose: We investigated the ability of amyloid-β-targeting liposomes, decorated with an anti-transferrin receptor antibody, to cross blood–brain barrier (BBB), comparing two antibody ligation techniques. Methods: Fluorescent or radiolabeled liposomes composed sphingomyelin/cholesterol and containing phosphatidic acid, known bind amyloid-β, were further functionalized RI7217. Two different techniques used attach RI7217 surface: biotin/streptavidin linkage thiol–maleimide covalent ligation....
Adoptive immunotherapy with T cells engineered tumor-specific cell receptors (TCRs) holds promise for cancer treatment. However, suppressive cues generated in the tumor microenvironment (TME) can hinder efficacy of these therapies, prompting search strategies to overcome detrimental conditions and improve cellular therapeutic approaches. CD1d-restricted invariant natural killer (iNKT) actively participate immunosurveillance by restricting myeloid populations TME. Here, we showed that...